The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the ...

Medtronic cardiovascular portfolio, coronary and renal denervation business senior vice-president and president Jason Weidman said: "Receiving TPT approval for our RDN catheter is an important ...

About a year ago, renal denervation procedures won a huge victory after finally being greenlit by FDA. Now two of the frontrunners in the space have received reimbursement.

Medtronic cardiovascular portfolio coronary and renal denervation business senior vice-president and president Jason Weidman said: “Medtronic is uniquely positioned to explore the blood pressure ...

First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety ...

In October 2024, Medtronic announced the start of an early feasibility study to evaluate the Sphere-9 catheter for treatment of ventricular tachycardia (VT), a cardiac arrhythmia in which the lower ...

which is part of the Medtronic Cardiovascular Portfolio. "The potential of Affera is limitless. We will continue to fulfill our commitment to innovation, including new indications, to advance ...

The Halloween 1957 power outage, caused by an explosion at the Black Dog power plant just south of Minneapolis, lasted for three hours and took the life of a young patient who was on an AC-powered ...

Affera™ Mapping and Ablation System With this approval, Medtronic is now the first and only company ... effective and efficient solution to this common and increasing problem in heart disease that ...